Drug Trial Radar · NCT06754462
A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis
Last checked: Nov 19, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Jan 10, 2025
Primary completion
Sep 2027
Study completion Sep 2027
Sponsor
- Lead sponsor
- Immunovant Sciences GmbHIndustry
- Sponsor type
- Industry
- First posted
- Dec 31, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2b, multicenter, double-blind, placebo-controlled, randomized withdrawal study is designed to assess the efficacy and safety of IMVT-1402 in adult participants with active, difficult-to-treat, anti-citrullinated protein autoantibody (ACPA) positive rheumatoid arthritis (RA).
Conditions
- Rheumatoid Arthritis
Interventions
IMVT-1402Drug
Administered once weekly by subcutaneous injection.
PlaceboDrug
Administered once weekly by subcutaneous injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants who maintain ACR20 response at Week 28Time frame: Week 28
Locations
83 sites in 11 countries. Site status is shown where the registry gives one.
Site Number - 1018
Mesa, Arizona
Site Number - 1019
Sun City, Arizona
Site Number - 1022
Covina, California
Site Number - 1028
San Leandro, California
Site Number - 1024
Temecula, California
Site Number - 1033
Tujunga, California
Site Number - 1023
Whittier, California
Site Number - 1020
Denver, Colorado
Site Number - 1015
Jupiter, Florida
Site Number - 1002
Miami, Florida
Site Number - 1027
Plantation, Florida
Site Number - 1005
Winter Park, Florida
Site Number - 1012
Zephyrhills, Florida
Site Number - 1001
Gainesville, Georgia
Site Number - 1034
Chicago, Illinois
Site Number - 1006
Cumberland, Maryland
Site Number - 1007
Hagerstown, Maryland
Site Number - 1031
Rockville, Maryland
Site Number - 1008
Worcester, Massachusetts
Site Number - 1021
Saint Clair Shores, Michigan
Site Number - 1030
Kansas City, Missouri
Site Number - 1010
Summit, New Jersey
Site Number - 1004
Charlotte, North Carolina
Site Number - 1035
Statesville, North Carolina
Site Number - 1000
Duncansville, Pennsylvania
Site Number - 1016
Jackson, Tennessee
Site Number - 1026
Memphis, Tennessee
Site Number - 1029
Murfreesboro, Tennessee
Site Number - 1037
Allen, Texas
Site Number - 1017
Colleyville, Texas
Site Number - 1036
Katy, Texas
Site Number - 1014
Mesquite, Texas
Site Number - 1013
Tomball, Texas
Site Number - 1025
Tomball, Texas
Site Number - 5003
Buenos Aires, Argentina
Site Number - 5001
Buenos Aires, Argentina
Site Number -5004
Buenos Aires, Argentina
Site Number - 5002
Buenos Aires, Argentina
Site Number - 5005
Buenos Aires, Argentina
Site Number - 5000
San Miguel de Tucumán, Argentina
Showing 40 of 83 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.